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Systemic and metabolic studies reveal that many biogenic polyamines play a pivotal role in 
different functions of the cells like growth, interaction and proliferation and hence can serve as 
potential targets for drug discovery and development. TETA has played a significant role in 
treatment of various diseases like Wilson´s disease as a synthetic drug molecule in clinics. The 
purpose of the project is to prepare deuterated TETA and its deuterated metabolites MAT and DAT 
as they also play important role in different biological processes. 
 
The first novel synthetic chemical route was initiated by using N, N- dibenzylethylenediamine as a 
starting reagent. After getting the product from the first step, the synthesis was continued by 
applying the chemical methods of reduction and acetylation to get the desired product. The different 
synthesis steps which were applied for the deprotection have not been successful in removing 
aromatic groups of the penultimate product hence this synthetic route did not work. 
 
The second synthetic route was initiated by using ethylenediamine as a starting reagent. After 
getting the product from the first step in dinitrile form, the synthesis was continued by introducing 
protective group BOC to the first product. Then methods of reduction and acetylation were applied 
to get the desired products. Reduction was also performed with the deuterated reducing agents in 
order to get the deuterated product. The last step of deprotection was performed successfully by 
using a mixture of 60% TFA in DCM to give one of our desired products DAT. 
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ABBREVIATIONS 
 
ACN                               Acetonitrile 
AdoMetDC                    S-adenosylmethionine decarboxylase 
AGEs                             Advanced glycation end products 
AMD                             Age-related molecular degeneration 
ADP                              Adenosine diphosphate 
ATP                               Adenosine triphosphate 
AZ                                 Antizyme 
Boc                                Tert-butoxycarbonyl 
DCM                             Dichloromethylene 
DEAD                           Diethylazodicarboxylate 
dcSAM                          Decarboxylase S-adenosylmethionine decarboxylase 
DMF                              Dimethyl formamide 
DNA                              Deoxy ribonucleic acid  
DFMO                           Difluoromethylornithine 
DAT                              N1, N10-diacetyltriethylenetetramine 
ERα                               Eestrogen receptor α 
Fmoc                             Fluorenylmethyloxycarbonyl 
FGF-1                           Fibroblast growth factor-1 
HPLC                           High performance liquid chromatography 
IF5A                             Initiation factor 5A 
IL                                 Interleukin 
KIR                              Inwardly rectifying K+ 
LV                               Left ventricular 
LC                               Liquid chromatography 
mRNA                         Messenger ribonucleic acid 
MAT                            N1-acetyltriethylenetetramine 
MTA                            5´-methylthioadenosine 
MAPK                         Mitogen-activated protein kinase 
MS                               Mass spectrometry 
MeOH                          Methanol 
NMDA                        N-methyl-D-aspartate 
NF-κB                         Nuclear factor kappa-light-chain-enhancer of activated B cells 
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NMR                          Nuclear magnetic resonance 
ODC                          Ornithine decarboxylase 
Put                             Putrescine 
PAE                           Polyaspartic ester 
PARP                        Poly (ADP-ribose) polymerase 
Spd                           Spermidine 
Spm                          Spermine 
SAM                        S-adenosylmethionine decarboxylase 
SSAT                       Spermidine/spermine N (1)-acetyltransferase 
SMO                        Spermine oxidase 
TETA                      Triethylenetetraamine 
THF                         Tetrahydrofuran 
TFA                         Trifluoroacetic acid 
TLC                         Thin layer chromatography 
TOF-MS                  Time of flight Mass spectrometer 
Ub                            Ubiquitination 
UV                           Ultra violet 
VEGF-1                   Vascular endothelial growth factor-1 
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1. Introduction 
 
Systemic and metabolic studies always play a very significant and vital role in drug discovery as 
they present the fundamental background which is essentially required before the clinical usage of 
drugs by giving information on the drug safety and efficacy. These studies are also pivotal in 
identifying new targets of therapeutic importance hence they play very important function in the 
development, testing and approval of the drugs. 
 
The main goal in this thesis work is to prepare deuterated triethylenetetraamine (TETA) and its 
terminally mono- and diacetylated deuterated metabolites, N1-acetyltriethylenetetramine (MAT) and 
N1, N10-diacetyltriethylenetetramine (DAT) respectively. After successful preparation of deuterated 
TETA and its metabolites, they will be used as internal standard in mass spectrometry (MS) for 
their analytical investigation. Due to very polar structure of TETA it elutes very inefficiently from 
conventional high performance liquid chromatography (HPLC) columns. It also absorbs poorly at 
accessible ultra violet (UV) detection wavelength. There are several methods which have been 
applied recently. One of them is fluorescent-labelling reagents method which is very helpful to 
derivatize TETA and its derivatives. The fluorescent-labelling method is very challenging and 
highly demanding as it requires a high level of accuracy while labelling analyte and also the 
detection of peaks weather they are separated from their respective metabolites or from other 
metabolites or not. An HPLC conductivity method has also been developed but it renders poor 
sensitivity due to high detection limit. TETA is spermidine (Spd) analogue and it is used for many 
clinical purposes nowadays. The detection of its two major metabolites MAT and DAT from 
biological samples matrix is quite difficult as these metabolites have the ability of undergoing 
structural rearrangement during their separation from the samples. In order to overcome all these 
analytical problems, one of the best way of detection of these molecules is to use quantitative mass 
spectrometry but for that purpose we require labelled derivatives of the original molecules. 
 
In order to prepare these molecules in laboratory we developed two synthesis routes starting from 
different starting materials and reagents. In first method our aim is to test a different synthetic route 
to prepare TETA, MAT and DAT starting from the N, N´- dibenzylethylenediamine. This synthetic 
route consists of four different steps of dinitrile formation, reduction, acetylation and deprotection 
of protective groups. The description of each synthetic step is given in experimental section in 
detail.  The synthesis is first tested with non deuterated derivatives. Every time a new deuterated 
molecule is synthesized, the synthetic route is first tested with the non-deuterated compounds. 
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In second method our aim is to test another different synthetic route to prepare TETA, MAT and 
DAT starting from the diethyleneamine. This synthetic route is also consists of five different steps 
including dinitrile formation, Boc protection, reduction, acetylation and deprotection. Step six 
reduction was performed with both deuterated and non- deuterated reagents. This scheme along 
with the description of each synthetic step is given ahead in experimental section in detail.  
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A. Literature Review 
 
2. Polyamines 
 
The term polyamines clearly indicates that these are a group of compounds containing more than 
one (-NH) amine group in their structure at different positions in the molecules. There has been an 
ever increasing interest during the last two decades in naturally occurring polyamines, putrescine  
(Put: 1,4-diaminobutane), spermidine (Spd: N-(3 aminopropyl)-1,4-butadiamine), (4-azaoctane-1,8-
diamine) and spermine  (Spm: N,N’- bis (3-aminopropyl-1,4-butanediamine), (4,9-diazadodecane-
1,12-diamine)(Figure 1).1 The fact behind this ever growing interest is that, their specific functions 
in cells is yet not much clear and still needs further investigation. Their unique nature and 
ubiquitous distribution, their peculiar behaviour in cells and increase in concentration in rapidly 
growing cells make this group of compounds an area of modern research for scientists. 
 
 
 
Figure 1 Structure of polyamines 
 
The first ever discovery of the polyamines was in 1678 when Antonie van Leeuwenhoek isolated 
some ‘tri-sided’ crystals from human semen.2 The empirical formula of these crystals was deduced 
in 19243 and it took further two years to synthesize these newly discovered products chemically.4 
Therefore the names Spd and Spm reflect the original discovery as they have been isolated from 
human semen. Put was first isolated from a bacterium Vibrio cholerae, but its common name was 
derived from the large quantities found in putrefying flesh.5 Polyamines are found almost in every 
living species, except two orders of Archaea, Methanobacteriales and Halobacterials.6 This strange 
behaviour  of their presence in almost every species across evolution is a peculiar feature in that it 
argues for their importance in cellular survival, but it can also be a short coming as it implies as a 
lack of specific function.7  
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Polycationic polyamines and their diamine precursor Put are apparently simple in structure, but they 
have very strong role to play as growth factors in eukaryotic cells.8The total intracellular 
concentration of polyamines is in the millimolar range; however, freely available amount of 
polyamines are considerably lower. This is partly because of the reason that they are having ionic 
interactions to various anions in the cell including nucleic acids, proteins and phospholipids. 
Polyamines play their role in the support of cell growth and survival. They are associated with the 
nucleic acids and maintenance of chromatin conformation. They regulate specific gene expressions 
and ion-channel functions.9The maintenance of membrane stability, provision of a precursor in the 
synthesis of eukaryotic translation initiation factor 5A (IF5A), free-radical scavenging and 
antioxidant activity is also come under the area of their influence .10, 11 
  
3. Synthesis of Polyamines 
 
3.1 In Vivo 
 
Biogenic polyamines are widely distributed in both animal and plant kingdom. Due to their 
immense impact in number of biological processes and variety of pharmacological attributes their 
biosynthetic pathway is of great importance, depicted in (Scheme 1). 
 
Scheme 1 Polyamine biosynthetic pathway (Adopted from 12) 
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There is a lot of data available including different articles and reviews describing the biosynthetic 
pathway of polyamines metabolism.18 By considering the importance of most vital steps which take 
place in most organisms, this pathway is briefly illustrated in this literature review. In first step an 
enzyme urease converts arginine to ornithine. In second step ortnihine is decarboxylated by the 
enzyme ornithine decarboxylase (ODC) to convert it to Put, the simplest polyamine which is the 
rate limiting step of the biosynthetic pathway. The aminopropyl groups in Spm and Spd are derived 
from decarboxylase S-adenosylmethionine decarboxylase (dcSAM), which is formed from S-
adenosylmethionine decarboxylase (SAM) in a reaction catalysed by S-adenosylmethionine 
decarboxylase (AdoMetDC). The aminopropyl transfer reactions are catalysed by spermine and 
spermidine synthases generating 5´-methylthioadenosine (MTA) in addition to Spm and Spd. 
 
3.2 In Vitro 
 
Beside this biosynthetic pathway which produces polyamines in living species, scientists have 
developed some synthetic pathways for the synthesis of the polyamines in laboratories to study their 
different biochemical properties in detail. The general synthetic pathways used in polyamines 
chemistry can be divided in to five main groups.  
 
3.2.1 Alkylation Reactions 
  
These are the most widely applied reactions for the synthesis of the polyamines. The extension 
of polyamine chains can be readily achieved by this process hence this method is progressively 
used for the synthesis of secondary, tertiary and quaternary amines from the primary amine 
groups (Scheme 2). 
 
Scheme 2 Alkylation of amines (Adopted from 12) 
 
As an example of the alkylation reaction in polyamines synthesis, the low cost corrosion 
inhibitors of steel can be prepared by reacting different polyamines with oleic acid at 1:1 molar 
ratio and then this amide mixture is made to react with benzyl chloride to get alkylated. This 
alkylated amide can be used as an active component for the inhibitory action against corrosion 
of steel in acidic and water-saline media.13 
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3.2.2 Reduction Reactions 
 
Reduction of variety of functional groups to the amino group using a range of reducing agents is 
one of the simplest methods for the synthesis of the polyamines. The functional groups which 
are mostly used in the preparation of polyamines are amides, nitriles, nitro groups and azides. 
The synthesis of polyamines has also been applied in polyamine chemistry by reduction of the 
Schiff´s bases. The general reaction first involves the condensation reaction followed by the 
reduction to give the substituted amines (Scheme 3). 
 
Scheme 3 Formation of amines by reduction of Schiff´s bases (Adopted from 12) 
 
 As an example of reduction reaction in polyamines synthesis, a novel macrobicyclic polyamine 
compound is synthesized through “tripod-tripod coupling” method using Schiff base 
condensation reaction. This formed complex is further reduced by sodium borohydride. This 
macrobicyclic compound is used in recognition of the oxalate.14     
 
3.2.3 Michael Addition Reactions 
 
This is also a general method for the synthesis of polyamines involving addition of amines to 
alkenes. In this method stepwise process of polyamine chains extension is usually applied to get 
the large sized polyamine chains. Tetraamines have been prepared by the addition of diamines 
with acrylonitrile giving the product by subsequent reduction (scheme 4). 
 
 
Scheme 4 An example of Michael addition reaction (Adopted from 12) 
 
As an example of Michael addition reaction in polyamines synthesis, a novel type of 
polyaspartic ester (PAE) chain extender having name PAE-f was prepared by Michael addition 
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reaction. The reagents 4,4´-methylenebis (2-Me cyclohexyl amine) is made to react with excess 
amount of dialkyl maleates. Then this residual dialkyl meleate is reacted with polyester 
polyamine Jeffamine D230. This two step synthesis considerably reduces the synthesis time in 
industry and gives the product a great tensile strength and module and hardness.15   
 
3.2.4 Mitsunobu Reactions 
 
It is kind of condensation reaction involving a primary or secondary alcohol and compound 
containing an acidic hydrogen (e.g. sulphonamide) in the presence of triphenylphosphine and 
diethylazodicarboxylate (DEAD). This reaction has been of great success in the production of 
substituted polyamines (scheme 5). 
 
 
Scheme 5 An example of the Mitsunobu reaction (Adopted from 12) (Reagents and Conditions: 
i) N-methyl-p-toluene sulfonamide:DEAD/THF/Ph3P, r.t; ii) N-Boc-p-toluene 
sulfonamide:DEAD/THF/Ph3P, r.t;) 
 
As an example of Mitsunobu reaction in polyamines synthesis, a compound 3,24-Bis(6-
chloropyridin-2-yloxy)cholane has been prepared by Mitsunobu reaction using a reagent 
cholane-3,24-diol. This reaction proved successful in synthesizing various polyaza macrocycles 
via palladium catalyzed amination with linear polyamines. Cyclic oligomers are produced as 
side product in these reactions. The polyamine nature of the reagent has been found responsible 
for the side formation of the cyclic oligomers.16 
 
3.2.5 Solid Phase Synthesis of Polyamines 
 
The increasing high demand for more complex polyamines, monofuntionalized polyamines, 
unsymmetrical polyamines and polyamines chemical libraries has laid greater stress to the 
application of the solid phase approach to the synthesis of these complex compounds. This 
method has many advantages over the traditional solution phase synthesis especially in the 
simplification of the reaction procedures, ease of purification steps and application to the 
 15
automated system. These reactions either involve the use of different resins as solid support for 
the reactants or commercially available substrate during the reactions (Scheme 6). 
       
      Scheme 6 An example of solid phase synthesis of polyamines (Adopted from 12) (Reagents and                    
conditions: i) Et3N; ii) B2H6, THF, 2 d, heat) 
 
For example, a selective protection of symmetrical oligoethylenimine precursors with 
Fluorenylmethyloxycarbonyl (Fmoc) followed by introduction of a carboxylic acid handle using 
cyclic anhydride has been used for the production of four different Fmoc-polyamino acid 
building blocks. This is a versatile solid-phase approach to develop sequence-defined 
polyamidoamines.17This simple method of building polyamine blocks along with the high 
efficiency of the solid-phase coupling reaction permit the unique synthesis of defined 
polycations.  
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4. Charge in Polyamines 
 
Charge is the fundamental property of any chemical entity that gives it peculiar properties in terms 
of its reactivity in different chemical and biological systems. The same implication of charge 
uniqueness can be applied on the polyamines.  Polyamines contain positive charge on each nitrogen 
atom in their structure at physiological pH. So it has been suggested that polyamines as simply 
‘supercations’, equivalent to one or two calcium or magnesium molecules. The characteristic 
feature which makes polyamines unique and distinct from the point charges of the cellular bivalent 
cations is that the charge on them is distributed along the entire length of the carbon chain.18 The 
positive charge on polyamines enables their interaction electrostatically with polyanionic bio-
macromolecules within the cells and tissues. 
 
Spd and Spm have ability to bridge up the gap between major and minor grooves of the 
deoxyribonucleic acid (DNA). They can act as a clamp holding together either two different DNA 
chains or the distinct part of the same molecule. The studies regarding interaction of polyamines 
have shown that they prefer to interact with individual chains of DNA rather than multiple DNA 
molecules.19 Crystallographic studies with polyamines indicate that they bind selectivity to the 
secondary structure of DNA.20 It also indicates polyamines preference for binding with pyrimidine 
residues, particularly thymidine.  This might be influenced by the neighbouring nucleotides and the 
nature of the secondary structure of DNA. Analogues of polyamines such as bis(ethyl) 
homospermine (‘BEHSpm’; ‘BE-4-4-4’) have an effect to alter the DNA-nuclear matrix interaction 
owing to their unique charge. Due to this polyamines create an impact in changing the structure of 
DNA and also influence its different functions.21 In nucleosome, deficiency of polyamines can 
results in partial unwinding of the DNA chains. They can also unmask the complementary 
sequences previously hidden in the nucleosome.22 These newly discovered sequences are potential 
sites for transcription regulating factors. The ability of polyamines to favour the formation of triplex 
DNA at neutral pH, may provide a mechanism by which polyamines regulate the transcription of 
the growth regulatory genes such as c-myc.23 
 
Polyamines can also interact with acidic phospholipids in cellular membranes in addition to their 
interaction with nucleic acids.24 Interaction of polyamines with phospholipids and proteins increase 
the rigidity of membranes by forming complexes with them.25 They may also play the role of 
antioxidant, preventing lipid per oxidation. Polyamines have been implicated in the regulation of 
many membrane bound enzymes, including tissues transglutaminase, adenylate cyclise, and some 
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ion channels such as N-methyl-D-aspartate (NMDA), inwardly rectifying K+(KIR) and voltage-
activated Ca2+ channels. 26 
 
Transport of polyamines across the mitochondria membrane in different cells occurs through 
controlled electrostatic interactions by a specific uniporter system. Although different catalytic rate 
constants values do not argue the occurrence of changes with of number of positive charges of the 
polyamine backbone, but Michaelis-Menten constant values highly support the dependence of 
electrostatic forces controlling the docking of substrate into polyamine channel. By considering this 
kinetic data in terms of Gibbs equation also proves the contribution of positive charges of 
polyamines in their transport.27     
 
Assuming the charge as an integral defining feature of the polyamines, then definitely single 
polycation would be sufficient enough to bring about the biochemical changes in the cells but this is 
not yet proven with the experimental facts. The most obvious choice for different reactions, 
synthesis and analysis would be Spm, due to its greatest charge, longest length and most flexibility. 
The sheer complexity and unique nature of polyamine regulation and metabolism compels that they, 
or their associated enzyme activities, have other critical functions within the cells, not based on 
solely on direct charge-charge interaction.18    
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5. Polyamines Analogues 
 
Chemical structural analogues are the compounds which are structurally very similar to the other 
compounds differing only by a certain component or a functional group or an atom but can be 
distinguished from each other on the basis of physical, chemical, biological and pharmaceutical 
properties. Analogues of polyamines are very important chemical species as they can be used in 
different studies due to their pharmacological and biological importance in drug discovery, 
development, design, analysis and synthesis.  
  
The targeted inhibition of specific biosynthetic enzymes yet not made substantial clinical success in 
the treatment of cancer in the polyamine metabolic pathway. But there is a huge amount of data that 
can determine polyamines function and metabolism as new rational targets for anti-neoplastic drug 
development and discovery. Therefore, the more logical and recently applied strategy has been to 
use the self-regulatory nature of the polyamine metabolism through the help of polyamine 
analogues. The main reasons to adopt this strategy were to overcome the limitations of specific 
enzyme inhibitors. The compensatory effect of up-regulation in biosynthesis and the uptake induced 
when one of the blocked biosynthetic enzymes was also considered.28 
 
The properties of best analogues which can act as inhibitors or anti metabolites would be to use the 
polyamine transporter to get entry into the cells. They should compete with natural polyamines for 
uptake and down-regulate multiple polyamine biosynthetic enzymes in order to prevent the 
potential increase in untargeted enzymes and up-regulate polyamine catabolism. This would cause 
greater deficiency of intracellular polyamine than would be afforded by simply decreasing 
synthesis. They are not substitute for the natural polyamines in growth-related functions but do 
exhibit tumour-selective activity. On the other hand, there are also some polyamine analogues 
which can replace the function of natural polyamines. For example, β-methylated Spd is capable of 
restoring the growth of Leishmania donovani and α-methylated Spm is used as an antidote in host-
parasite system where inhibitors of the polyamine biosynthesis are used for the therapy of 
leishmaniasis.29 
 
Different classes of the antimetabolic compounds based on the way that how the polyamine 
backbone in any parent molecule has been substituted, can be discussed as under. Namely these are 
symmetrically substituted, asymmetrically substituted, conformation ally restricted, oligoamines 
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and macrocyclic polyamines. All the above mentioned polyamines analogues only act polyamines 
antimetabolites. 
 
5.1. Symmetrically substituted bis(alkyl)  
 
The first group of compounds which meet the properties of best analogues criteria were synthesized 
and reported by Bergeron and his co-workers named as bis(alkyl) polyamines.30The elegance of 
these compounds lies in their simplicity.  Although polyamines have got self regulating metabolism 
but due to the presence of several amine oxidases, the addition of natural polyamines and similar 
compounds having primary amines is dangerous. These enzymes can metabolize the free amino 
group to toxic species which can cause several side effects.31 In order to solve this problem alkyl 
groups were symmetrically introduced to the primary amines of the general polyamine structure to 
create various polyamine analogues. 
 
Despite of their own unique cytotoxic activity, in the early stages Spm and Spd analogues provided 
the similar results as were obtained by using difluoromethylornithine (DFMO). There was observed 
a general decrease in growth rate. These initial studies also revealed that Spm analogues can inhibit 
growth in more viable way in nature than Spd analogues.32This new discovery leads to the 
designing of subsequent generations of the analogues. 
 
The first sign of cytotoxic effects of this class of compounds came from the response of DFMO-
resistant human non-small-cell lung cancer line, NCI H157. It responded in rapidly cytotoxic 
manner to the treatment with the analogue N1,N8-bis(ethyl)spermidine 33 (figure 2). 
 
 
Figure 2 Examples of symmetrically substituted polyamine analogues (adopted from 28) 
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However, more significant about this demonstration was that the response to these agents was 
specific to the particular phenotype of the cells. When a DFMO-sensitive human small-cell-lung-
cancer line, NCI H82, was compared with the DFMO- resistant human non-small-cell lung cancer 
line, NCI H157, with respect to their response to the bis(ethyl)polyamines analogues, it was 
concluded that the NCI H82 cells were considerably more resistant to the bis(ethyl)polyamines than 
the NCI H157 cells.34 
 
5.2. Asymmetrically substituted  
 
Symmetrically substituted analogues might still have their clinical importance but their utility is 
limited. The reason behind this is that, Bergeron and his colleagues modified only symmetrical end 
groups rather than to change the number of carbons between the amines that could have proved 
clinically more useful and potent. The new strategy which has been applied recently to extend this 
idea of the bis(alkyl) polyamine analogues to alter the basic polyamine backbone structure by 
asymmetric substitution. The analogues of Spm and norSpm were the most active of the 
symmetrically substituted analogue. Hence primary importance was given to Spm and norSpm 
backbone. 
 
The early members of this class showed quite significant antiproliferative activity (figure 3).The 
results obtained from N1-propargyl-N11-ethylnorspermine and N1-cyclopropyl-methyl-N11-
ethylnorspermine were demonstrating cell-type-specific cytotoxity. This property is linked with the 
induction of SSAT. These findings match closely to the results observed for the symmetrically 
substituted analogues.35 Clinical investigations of the N1-cycloheptylmethyl-N11-ethylnorspermine 
and (S)-N1-(2-methyl-1-butyl)-N11-ethyl-4,8-diazaundecane have proved that slight alterations in 
analogues structure can cause a fruitful effect on different cellular reaction pathways. The analogue 
N1-propargyl-N11-ethylnorspermine rapidly induces apoptosis in non-small-cell lung cancer in 
comparison with the other symmetrically and asymmetrically substituted analogues which induce 
SSAT.36The analysis of Cell cycle revealed that, treatment with analogue produces profound G2/M 
block coincident with interference with normal tubulin polymerization. It is of great worth to note 
that, although (S)-N1-(2-methyl-1-butyl)-N11-ethyl-4,8-diazaundecane has significantly induce 
SSAT and effects a G2/M block, the other asymmetrically substituted analogues have very minute 
effect on cell cycle with respect to G2/M transit. N1-cycloheptylmethyl-N11-ethylnorspermine and 
(S)-N1-(2-methyl-1-butyl)-N11-ethyl-4,8-diazaundecane can also induce SMO, the activity which is 
supposed to contribute to their antiproliferative action.37 
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A large series of asymmetrically synthesized analogues have been reported to confirm anti-tumour 
activity when examined against different types of tumour cells. The synthesis of these 
asymmetrically substituted analogues showed that slight changes in the structure can lead to 
significant biological results based on their anti-tumour activity. The most important characteristic 
revealed by this synthesis is that, multiple functional groups can be added to the same polyamine 
backbone, which could potentially increase targeting capacity of different compounds. 
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(S)-N1-(2-methyl-1-butyl)-N11-ethyl-4,8-diazaundecane  
Figure 3 Examples of asymmetrically substituted polyamine analogues (adopted from 28) 
 
5.3. Conformationally restricted  
 
Third approach which was used to expand the area of influence of the original polyamine analogues 
was to restrict the conformation of different analogues. It was done by introducing modifications 
into the methylene chains between the amines. The molecular flexibility of the natural polyamines 
is due to their alkylamine structure. This flexibility in the molecular structure helps to facilitate their 
interaction with multiple cellular anions. Frydman and his co-workers pointed out that by restricting 
the free rotation of the carbon-to-carbon bonds, the resulting compounds would have altered and 
potentially therapeutic activity (figure 4).38 Addition of unsaturated linkages and cyclic functional 
groups into bis(ethyl)tetramines and bis(ethyl)pentamines resulted in compounds with characteristic 
antiproliferative activities in various experimental models. 
 
Figure 4 Examples of conformationally restricted polyamine analogues (adopted from 28) 
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Two main representative of this class that have shown efficient antiproliferative preclinical results 
are CGC-11047 and CGC-11093. The CGC-11047 is based on N1,N12-bis(ethyl)spermine, with a 
double bond in the central 4-carbon methylene bridge while CGC-11093 is based on N1,N14-
bis(ethyl)homospermine, with cyclopropyl bond in the central 4-carbon methylene bridge. The 
addition of double bond into N1,N12-bis(ethyl)spermine resulted in a compound with significantly 
increased antiproliferative activity compared with its original form, but with minimal toxicity. The 
similar behaviour is observed in the activity and toxicity when cyclopropyl bond is introduced into 
N1,N14-bis(ethyl)homospermine. This introduction of conformational restrictions into the synthetic 
processes of analogues of polyamines has allowed for the creation of several novel compounds with 
characteristic and distinct ranges of activities and toxicities.39 
 
Both CGC-11047 and CGC-11093 are in clinical trails. The CGC-11093 is in phase I trail regarding 
their impact on SSAT and SMO expression. The CGC-11047 is not only in phase I trails as a single 
agent but also in a phase Ib trail in combination with other pharmaceutically important agent that 
would increase its targeting specificity. Additionally, CGC-11047 is also under phase II clinical 
trails and enrolling patients with diseases like hormone non-responsive metastatic prostate cancer 
and pancreatic cancer. Beside a great similarity in structure, only CGC-11047significantly induces 
SSAT and SMO as compared to CGC-11093.40 This induction does play an important role in 
tumour-cell response to CGC-11047. But this induction is not a property which is must require for 
pharmacological activity. It is only because of the reason that CGC-11093 and other important 
analogues do have a slight impact on SSAT and SMO expression, but are nevertheless active 
compounds. 
 
A series of studies on these two analogues and others revealed their potency against a disease 
known as age-related molecular degeneration (AMD). It is an ailment characterized by vascular 
proliferation, as is diabetic retinopathy. In several mouse models of this disease it has been 
represented that these two analogues not only prevent the disease but can also reverse the situation 
of vascular lesions. These studies have led to the initiation of phase I clinical trial for AMD.41 These 
two polyamine analogues are also anti-angiogenic in these mouse models, an activity related to 
antineoplastic activity. Another important fact is that, those polyamine analogues which are actively 
transported, can be administrated subconjunctivally to the eye. Their this characteristic property is 
in contrast to the recently approved drugs for AMD which must be injected indirectly to the eye.42 
 
 
 23
5.4. Oligoamines  
 
The antiproliferative activity of the specific polyamine analogues has been demonstrated on the 
basis of a mechanism which explains their ability to interact with nucleic acids and other 
intracellular polyamine-binding sites.  A large series of studies have shown the interaction of natural 
polyamines with DNA and chromatin material. This phenomenon led to the importance of selection 
of the specific polyamine analogue for targeting a specific site. By considering these important 
studies, scientists introduced the strategy of increasing the number of protonatable imines so that 
the resulting compounds would have increased affinity for DNA. This will turn them to be more 
potent antiproliferative agents.43They synthesized a series of oligoamines in both saturated and 
conformationally restricted unsaturated forms containing 8-14 amines (figure 5). In this way a 
fourth class of analogues have been created with a potential of pharmacological action.      
 
Figure 5 Examples of important oligoamines (adopted from 28) 
 
These compounds demonstrated potent (submicromolar) antiproliferative activity in human prostate 
cell lines.44 This characteristic behaviour can be  correlated well with their ability to aggregate DNA 
in vitro. A representative oligoamine, CGC-11144, showed significant antitumour activity against 
human breast-cancer cells both in vitro and in vivo. It exhibited a great antiproliferative effect when 
treated with established MDA-MB-231-tumour-bearing nude mice, using a twice a week schedule. 
CGC-11144 induces many significant biological phenomenon including apoptotic cell death, 
caspase 3 activation, mitochondrial cytochrome c release, increased expression of the pro-apoptotic 
BCL2-assoiciated X (BAX) protein, poly (ADP-ribose) polymerase (PARP) cleavage  and 
decreased the release of anti-apoptotic B-cell CLL/lymphoma 2 (BCL-2) protein. CGC-11144 
treatment also lessens ODC activity. It also has very minute impact on the expression of the 
polyamine catabolic enzymes SSAT and SMO.45 This decrease in the ODC activity is most 
probably because of the increase ODC antizyme protein production in the cells exposed to the 
oligoamines. A recently demonstrated study showed that alogoamines can change the expression of 
oestrogen receptor-α (ERα) in a highly selective way. Most specifically, the oligoamines CGC-
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11144, CGC-11159 and CGC-11172 downregulate the transcription of the Erα through apparent 
disruption of Sp-1 transcription factor (SP1) family member binding to the Erα promotor.46 These 
findings proposed a novel anti-oestrogen effect by the oligoamines that might provide another 
strategy for the best cancer prevention or at least a therapy for it. 
 
5.5. Macrocyclic polyamines 
 
This is a unique class of polyamine analogues that possess various multiple functions with the cells 
including DNA binding, complexation of the transition metals, DNA cleavage and depletion in the 
rate ATP production. This interesting class of analogues has recently been reviewed by Liang and 
co-workers.47 It is in the early stages of its development. Beside this fact they have shown a great 
promise to be considered as a potent anti-viral and anti-tumour agents (figure 6).48 
 
Figure 6 Examples of macrocyclic polyamine analogues (adopted from 28) 
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6. Potential targets of the polyamine analogues 
 
Polyamines analogues are involved in competing with natural polyamines for uptake by the 
polyamine transporters. They are also playing a key role in several biochemical processes in cells 
and hence are having many potential targets. The potential targets of polyamine analogues revised 
by according to a review28 can be listed as under. 
 
a) They can induce the necessary alterations to go through the reading of regulatory stop of 
antizyme (AZ) mRNA. 
b) AZ is known to bind carboxyl terminus of ornithine decarboxylase (ODC) monomers which 
leads to the breakdown of ODC by the 26S proteosome. 
c) AZ also have the ability to down regulate the polyamine transporter by a mechanism which 
is currently unknown.49 
d) polyamine analogues can increase the rate of ODC degeneration that actually decrease the 
rate of SSAT protein degrading by blocking the ubiquitination (Ub) of SSAT and its 
subsequent destruction by the 26S proteosome. 
e) Natural polyamines and their analogues present in excess quantities can reduce the 
efficiency of ODC and S-adenosylmethionine decarboxylase (AdoMetDC) mRNA 
translation.50 
f) The analogues of polyamines not only increase the efficiency at which SSAT mRNA is 
translated but can also increase the stability of mRNA. 
g) The analogue treatment and interference with polyamine metabolism do have direct effects 
on the transcription of the several important growth regulatory genes as well as on genes 
that are involved in polyamine metabolism.  
h) Polyamine analogues also lead to an increase in efflux of the polyamines and their acetyl 
derivatives through the diamine transporter. 
i) The primary function of natural polyamines is through their ionic interactions with 
important cellular anions. Hence it can be concluded that there is a huge possibility that 
some of the antiproliferative effects of polyamine analogues and treatment that reduce 
intracellular polyamine concentrations are a result of either direct competition for binding to 
these critical sites or a displacement of natural polyamines from these critical sites.51 
j) All of these above mentioned process can profoundly affect cellular proliferative capacity.    
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7. Triethylenetetraamine (TETA) 
 
Triethylenetetraamine (TETA), Trien, is a modern alternative of D-penicillamine for the treatment 
of the patients suffering from Wilson´s disease which is characterized by the excess accumulation 
of copper metal in human brain. TETA is a 219.2 MW ligand with six CH2 groups which are 
arranged as three ethylene segments (figure 13). It is a polar hydrophilic chelator that binds to 
excess free body copper and competes with albumin for binding copper.52 It is excreted from the 
body after binding as TETA-CuII complex as TETA mobilizes copper in the kidneys and helping it 
pass it out through urine. It is bipositively charged molecule at physiological pH and structurally 
isosteric charge-deficient analogue of spermidine.53 Its laboratory preparation was first initiated in 
Berlin, Germany and was made as dihydrochloric salt in 1861 and 1896 respectively. Its ability to 
chelate CuII was first investigated at Cambridge University in 1925. CuII prefers nitrogen as ligand 
over oxygen and as TETA has four nitrogen groups. These nitrogen groups can occupy four 
coordination sites of CuII to form a strongly bound TETA-CuII complex that helps them to make a 
square-planar geometry in which CuII is most stable (Figure 7). Therefore, it binds CuII very firmly 
having dissociation constant of 10-15 mol/L at Ph 7.0.54 By increasing the urinary excretion of 
copper, TETA tends to have the ability of decreasing intestinal absorption of copper showing its 
two fold ability to act on copper metabolism.55  
 
Figure 7 Structure of TETA and TETA-CuII complex 
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8. Biological Importance of TETA 
 
TETA and different physiological polyamines (e.g. Spm and Spd) share the similar intestinal uptake 
mechanism in human bodies. In this mechanism, there occurs a charge-interaction between the 
negative-charge of the inner membrane layer and the polycation. In human bodies, the transporting 
agent for the transport of polyamines is glypican-156, so, as TETA and other physiological 
polyamines share the same mechanism of uptake, it seems that they use the same transporter 
glypican-1 to cross the biological membranes in different tissues and cells. By using this 
transporter, polyamines are instantaneously transported into the mitochondria of the cells 
electrophoretically.57 After the absorption of TETA into the mitochondria, it is quickly metabolized 
to its two most important metabolites named as N1-acetyltriethylenetetramine (MAT) and N1, N10-
diacetyltriethylenetetramine (DAT) 58 (figure 14).   
 
 
Figure14 Structure of DAT and MAT 
 
The rate of excretion of TETA and its metabolites in their free and Cu-bound forms is much faster 
in other mammals like rodents as compared to humans but the mechanism of excretion is not much 
clear. The Na+/spermine antiporter which present in renal brush-border is thought to be responsible 
for the active secretion of the all the straight-chain polyamine compounds that contain more than 
four amino groups and thus is regarded as mediator for the excretion of TETA and its metabolites as 
well.59 The total rate of absorption TETA is extremely low and it varies a lot in different patients 
suffering from Wilson´s disease. The rate of recovery of TETA from excretion in human is only 1-
2% which is extremely low but acetylated forms of TETA such as its metabolites MAT and DAT 
are recovered at significantly good rate that is 8-11% of the orally administered dose. The rate of 
recovery of TETA and its metabolites MAT and DAT in Cu-bound form or as free molecules after 
excretion is still unclear but it can be concluded that it is excreted predominantly in its acetylated 
forms. The pattern of excretion also varies significantly among different human beings ranging 
from 6 to 26 hours in the case of unmodified form and acetylated forms respectively. The major 
side effect which can arise with the treatment from TETA is the iron deficiency anemia in children 
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and pregnant women. However, this problem can be comprehended successfully by giving iron 
supplementation along with treatment of TETA considering the dosage time appropriately.60   
 
Metabolic changes in diabetes, especially those that results in accumulation of advanced glycation 
end products (AGEs) in the extracellular matrix, are the reason of accumulation of excess extra 
cellular CuII in the extracellular matrix, resulting tissue-Cu imbalance that can cause heart failure. 
TETA´s ability to remove excess extracellular CuII enables it to be helpful in improving the 
conditions of the patients with left ventricular hypertrophy in diabetes.61 Many clinical studies of 
TETA´s treatment has proved that it can act to increase the strength of cardiomyocyte structure, 
alleviation of heart failure with diabetic patients and normalization of the cardiac diastolic function. 
The oral treatment of TETA can cause significant improvement in decreasing the elevated levels of 
LV collagen and β1-integrin in the presence of constantly high blood circulating sugar. However, 
treatment with TETA can considered as a novel potential therapeutic channel in patients suffering 
from heart failure in diabetes but the possibility of causing some severe side effects can not be 
excluded. As the mechanism of action of TETA in diabetes is not much clear so, it can cause a 
depletion of copper in patients suffering from diabetes.62 
 
TETA is not only a therapeutic orphan drug for treating Wilson´s disease and patients suffering 
from heart failure in diabetes but can also be considered as a potential therapeutic agent for  the 
treatment of cancer. There are different mechanisms that have been proposed that how TETA can 
act on different tumour cells but the confirmation of any mechanism by which TETA proceeds in 
the cancerous cells is yet to be known. One possible mechanism of action of TETA to show its 
cytotoxicity on tumour cells is to inhibit telomerase activity. Telomerase plays a key role in cellular 
immortalization and tumourigenesis, which are appeared in more than 80% of all human cancers. 
The reports suggested that TETA has the ability to stabilize both inter and intra-molecular G-
quadruplex because of its tendency to act as a ligand for G-quadruplex.63 
 
TETA´s other mechanism of action against cancer can be anti-angiogenesis. Chelation of copper by 
TETA can play a very vital role to suppress several angiogenic mediators. These mediators include 
vascular endothelial growth factor-1(VEGF-1), fibroblast growth factor-1(FGF-1), interleukin-1 
(IL-1), IL-6, IL-8 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). By 
suppressing the activities of these modulators, it is thought to exhibit its properties as anti-
angiogenic effects in cancerous cells.64  Treatment of TETA could overcome cisplatin resistance in 
human ovarian cell culture via inhibition of superoxide dismutase 1/ Cu / Zn superoxide dismutase. 
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TETA can also induce apoptosis in murine fibrosarcoma cells by activating p38 mitogen-activated 
protein kinase (MAPK) pathway. One other way of introducing apoptosis could be chronic 
depletion of copper by chelation with TETA, which might induce the expression of antioxidants and 
triggers apoptosis in neuroblastoma cells.65  
 
All these above mentioned mechanisms of action against tumour cells are only suggested routes by 
which polyamines interact within a biological system of an organism. One clear mechanism of 
action in cancer pharmacology of TETA is yet to be determined. Although, non of the mechanisms 
can be strictly applied to cancer pharmacology but all these different mechanism might have their 
role to play in different cancer tissues or combination of different mechanism might act to inhibit 
the growth of cancer cells. Anyhow, complete knowledge different mechanism of TETA´s 
pharmacology in different cancerous cells can helpful in developing different drugs for the 
treatment of different diseases especially cancer.  
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9. Analysis of TETA, MAT and DAT  
TETA is mostly used in clinics in the form of dihydrochloride salt as it dissolves in aqueous 
solutions and appears as free-based TETA. Most recently its disuccinate form has also been 
developed.66 The analytical investigation and detection of TETA and its two major metabolites, 
which are actually it´s terminally mono and diacetylated forms, known as MAT and DAT is very 
difficult. Due to very polar structure of TETA it elutes very inefficiently from conventional high 
performance liquid chromatography (HPLC) columns. It also absorbs poorly at accessible ultra 
violet (UV) detection wavelength. There are several methods which have been applied recently. 
One of them is fluorescent-labelling reagents method which is very helpful to derivatize TETA and 
its derivatives.67 The fluorescent-labelling method is very challenging and highly demanding as it 
requires a high level of accuracy while labelling analytes and also it presents difficulty in the 
detection of peaks weather they are separated from their respective metabolites or from other 
metabolites or not. This problem of inconsistent labelling of targeted analytes can give rise a 
difficulty of complex chromatogram.  An HPLC conductivity method has also been developed but it 
renders poor sensitivity due to high detection limit.68 In recent days, a method combining liquid 
chromatography (LC) and mass spectrometry (MS) has been developed.69 It can be used to detect 
TETA and its two major metabolites MAT and DAT simultaneously in the aqueous solution, 
providing better sensitivity for detection and analytical power. Now in the presence of the liquid 
chromatography (LC) combined with tandem mass spectrometry (MS-MS), LC-MS-MS 
technology, a method with higher resolution, sensitivity and accuracy can be developed that will be 
used to investigate TETA and its major metabolites in the human samples, which will ultimately 
help us to predict its future pharmacology and clinical usage of TETA. 
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B. Experimental Part 
 
10. Materials and Methods 
 
All of the materials were purchased from the commercial suppliers and used without further 
purification. The solvents that were dried and distilled are acetic anhydride, methanol, ACN, TFA, 
THF, DMF and DCM. Thin layer chromatography was performed on silica gel, Kiesel gel. 
Chromatography column was carried out on silica gel. The NMR analysis was done on Bruker 
AVANCE DRX spectrometer operating at 500.13 MHz. The mass of the Deuterated product was 
measured on QSTAR XL MS/MS spectrometer using electrospray ionization.  
 
11. Synthesis 
 
11.1. Synthesis of 2,2'-(ethane-1,2-diylbis(benzylazanediyl))diacetonitrile (1) 
 
 
N, N´- dibenzylethylenediamine (2.0 g, 8.3 mmol), chloroacetonitrile (1.885 g, 24.97 mmol), K2CO3 
(6.9 g, 49.93 mmol), KI (1.38 g, 8.31 mmol) were measured in a round bottomed 100 ml flask and 
dried DMF (40 mL,) was added. The mixture was refluxed for 4 hours in nitrogen atmosphere dried 
in vacuo. The product was dissolved in DCM (15 mL) and washed with water (5x20 mL). Organic 
layer was separated and dried with MgSO4. After filtering the product, it was dried again in vacuo 
to give 2,2'-(ethane-1,2-diylbis(benzylazanediyl))diacetonitrile (1) as brown solid (1.3562 g, 68%) 
which melted at 89 °C. 
 
1H NMR (500.0 MHz, CDCl3)  δ: 3.665(4H,s),3.516(4H,s),2.787(4H,s),7.234-7.332(10H,m) 
13C NMR (125.8 MHz, CDCl3) δ: 136.67, 114.74, 126.97-129.01(5 C), 58.91, 51.26, 41.37 
 
11.2. Synthesis of (3,6-dibenzyl)-1,8-diamino-3,6-diazaoctane (2) 
 
 
LiAlH4 (0.0954 g, 2.51 mmol) in finely grounded form was dissolved in diethyl ether (20 mL) 
refluxed in nitrogen atmosphere for one hour. After one hour, the reaction mixture was cooled down 
for 30 minutes at 0-4 °C in an ice bath. 1 was dissolved (0.2 g, 0.62 mmol) in diethyl ether (20 mL) 
and added slowly to the reaction mixture drop wise in approximately 20 minutes with gentle 
mixing. The mixture was warmed up to room temperature and refluxed again for four hours. After 
four hours, reaction mixture was cooled to 0-4 °C in ice bath. The reaction was stopped by adding 
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0.2 mL of distilled water and 0.6 mL of 5M NaOH in the reaction mixture. The mixture was 
warmed up to room temperature and mixed gently for 30 minutes. The organic layer was filtered 
and the residue was washed with DCM (3x10 mL). MgSO4 was added in organic part and the 
product was dried in vacuo after filtration. The product was purified on TLC using MeOH as a 
solvent giving (3,6-dibenzyl)-1,8-diamino-3,6-diazaoctane (2, 0.119g, 60%)as white crystals. 
 
1H NMR (500.0 MHz, MeOD)  δ: 3.678(4H,s),2.599(4H,m),2.616(4H,m),2.800(4H,s),7.228-
7.274(10H,m) 
13C NMR (125.8 MHz, MeOD) δ: 137.69, 127.97-128.01(5 C), 64.91, 57.37, 52.28, 38.50 
 
11.3. Synthesis of N, N´-((ethane-1, 2- diylbis(benzylazanediyl))bis(ethane-2,1-
diyl))diacetamide (3) 
 
 
2 (0.1800 g, 0.55 mmol) was dissolved in toluene (20 mL) and pre-distilled pure and dried acetic 
anhydride (0.125 g) was added slowly.  The reaction mixture stirred for one hour at room 
temperature and the solvents were dried away in vacuo. Product was purified on silica gel column 
chromatography using MeOH as eluent giving N, N´-((ethane-1, 2-diylbis 
(benzylazanediyl))bis(ethane-2,1-diyl))diacetamide (3, 0.12g, 67%) as yellowish crystals. 
 
1H NMR (500.0 MHz, MeOD)  δ: 1.863(6H,m),3.279(4H,s),2.592(4H,m),2.513(4H,m), 
3.547(4H,s),7.244-7.252(10H,m) 
13C NMR (125.8 MHz, MeOD) δ: 171.1, 138.20, 127.85-129.77(5 C), 65.10, 58.78, 53.63, 36.97, 
21.63 
 
11.4. Synthesis of N1,N10-diacetyltriethylenetetramine (DAT) 
 
 
In first method of deprotection step, Pd/C 5% (0.015 g, 0.14 mmol) was measured in two necked 
flask. 3. (0.1000 g, 0.24 mmol) was dissolved in MeOH (5 mL) and added in the flask containing 
the catalyst. The reaction vial was put to the catalytic hydrogenation chamber at 1 atm standard 
pressure in room temperature for 4-5 hours. The product was filtered through celite plug and dried 
in vacuo. 
 
In second method of deprotection step, PdCl2 100% (0.010 g, 0.05 mmol) was measured in two 
necked flask. 3 (0.1000 g, 0.24 mmol) was dissolved in MeOH (20 mL) and added in the flask 
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containing the catalyst. The reaction vial was put to the hydrogenation at normal pressure in room 
temperature for 4-5 hours. The product was filtered through celite plug and dried in vacuo. 
 
In third method of deprotection step, PdCl2 100% (0.010 g, 0.05 mmol) was measured in two 
necked flask. 3 (0.1000 g, 0.24 mmol) was dissolved in MeOH (20 mL) and added in the flask 
containing the catalyst. The reaction mixture was hydrogenated for overnight at 4 bar pressure. The 
product was filtered through a celite plug with MeOH (20 mL) and dried in vacuo. 
 
In fourth method of deprotection step, Pd/C 5% (0.015 g, 0.14 mmol) was measured in high 
pressure hydrogenation flask. 3 (0.1000 g, 0.24 mmol) was dissolved in MeOH (19 mL) and added 
acetic acid (1 mL) was added and put it to the reaction vial. The reaction mixture was hydrogenated 
for overnight under 4 bar pressure. The product was filtered through a celite plug with MeOH (20 
mL) and dried in vacuo. 
 
11.5. Synthesis of 2,2'-(ethane-1,2-diylbis(azanediyl))diacetonitrile(4) 
 
Ethylenediamine (0.5 g, 8.3 mmol), chloroacetonitrile (1.319 g, 1.65 mmol), K2CO3 (2.3 g, 1.66 
mmol) were measured in a round bottomed 100 ml flask and dried ACN (20 mL) was added. The 
mixture was refluxed for 4 hours with vigorous stirring in nitrogen atmosphere. The reaction 
mixture filtered and dried in vacuo. The product was dissolved in DCM (10 mL) to remove the 
impurities and dried in vacuo again to give 2,2'-(ethane-1,2-diylbis(azanediyl))diacetonitrile (4) as 
white colour powder (0.4064 g, 81%). 
 
1H NMR (500.0 MHz, CDCl3)  δ: 3.599-3.701(4H,m),2.87(4H,s) 
13C NMR (125.8 MHz, CDCl3) δ: 118.01, 47.87, 37.58 
 
11.6. Synthesis of di-tert-butyl ethane-1,2-diylbis((cyanomethyl)carbamate)(5) 
 
4 (0.2410g, 1.74 mmol) was dissloved in DCM (20 mL) in a 100 ml round bottomed flask. A 
solution of di-t-butyl dicarbonate (Boc2O) (0.7804g, 3.57 mmol) was made in DCM (10 mL). This 
solution was added slowly drop wise to the first flask keeping it in an ice chamber. The contents of 
the flask were stirred for 1 hour at room temperature. The solvent was evaporated and dried in 
vacuo to give di-tert-butyl ethane-1,2-diylbis((cyanomethyl)carbamate) (5) white long shaped 
crystals (0.5021g, 64%) 
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1H NMR (500.0 MHz, CDCl3 )  δ: 4.202(4H,s),3.427(4H,s),1.333-1.587(18H,m) 
13C NMR (125.8 MHz, CDCl3) δ: 154.78, 116.24, 80.27, 47.98, 40.29, 28.43(3 C) 
 
11.7. Synthesis of di-tert-butyl ethane-1,2-diylbis((2-aminoethyl)carbamate)(6a) 
 
LiAlH4 (0.337 g, 8.55 mmol) in finely grounded form was dissolved in diethyl ether (20 mL) and 
refluxed in nitrogen atmosphere for one hour. After one hour, the reaction mixture was cooled down 
for 30 minutes at 0-4 °C in an ice bath. 5 was dissolved (0.5 g, 1.47 mmol) in diethyl ether (20 mL) 
and added slowly to the reaction mixture drop wise in approximately 20 minutes with gentle 
mixing. The mixture was warmed up to room temperature and refluxed again for four hours. After 
four hours, reaction mixture was cooled to 0-4 °C in ice bath. The reaction was stopped by adding 
0.6 mL of distilled water and 0.3 mL of 5M NaOH in the reaction mixture. The mixture was 
warmed up to room temperature and mixed gently for 30 minutes. The organic layer was filtered 
and the residue was washed with hot DCM (3x10 mL). MgSO4 was added in organic part and the 
product was dried in vacuo after filtration. To this product ethyl acetate (10 mL) and acetic acid 
(0.02 mL) were added to get the desired crystals of the product. Solvents were evaporated again in 
vacuo giving di-tert-butyl ethane-1,2-diylbis((2-aminoethyl)carbamate)(6a) (0.275g, 55%) as foamy 
white crystals. 
 
1H NMR (500.0 MHz, MeOD)  δ: 3.025(4H,s),3.279(4H,s),3.384(4H,d),1.45(18H,s) 
13C NMR (125.8 MHz, CDCl3) δ: 155.78, 80.20, 50.98, 46.35, 38.59, 28.81(3 C) 
 
11.8. Synthesis of deuterated di-tert-butyl ethane-1,2-diylbis((2-
aminoethyl)carbamate)(6b) 
 
LiAlD4 (0.297 g, 7.08 mmol) in finely grounded form was dissolved in diethyl ether (20 mL) 
refluxed in nitrogen atmosphere for one hour. After one hour, the reaction mixture was cooled down 
for 30 minutes at 0-4 °C in an ice bath. 5 was dissolved (0.4 g, 1.18 mmol) in diethyl ether (20 mL) 
and added slowly to the reaction mixture drop wise in approximately 20 minutes with gentle 
mixing. The mixture was warmed up to room temperature and refluxed again for four hours. After 
four hours, reaction mixture was cooled to 0-4 °C in ice bath. The reaction was stopped by adding 
0.6 mL of distilled water and 0.3 mL of 5M NaOH in the reaction mixture. The mixture was 
warmed up to room temperature and mixed gently for 30 minutes. The organic layer was filtered 
and the residue was washed with hot DCM (3x10 mL). MgSO4 was added in organic part and the 
product was dried in vacuo after filtration. To this product ethyl acetate (10 mL) and acetic acid 
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(0.02 mL) were added to precipitate the desired crystals of the product. Solvents were evaporated 
again in vacuo giving di-tert-butyl ethane-1,2-diylbis((2-aminoethyl)carbamate)(6a) (0.22g, 55%) 
as foamy white crystals. 
 
MS Data: m/z 389.2738[M+K]+, 373.2985[M+Na]+,351.3150[M+H]+,251.2559[M+H-Boc]+   
 
11.9. Synthesis of di-tert-butyl ethane-1,2-diylbis((2-acetamidoethyl)carbamate)(7) 
 
6a (0.200 g, 0.42 mmol) was dissolved in dry ACN (20 mL) and pre-distilled pure and dried acetic 
anhydride (0.0438 g) was added slowly.  The reaction mixture stirred for one hour at room 
temperature and the solvents were dried away in vacuo. Product was purified on silica gel column 
chromatography using MeOH as eluent giving di-tert-butyl ethane-1,2-diylbis((2-
acetamidoethyl)carbamate)(7)(0.080g, 40%) as yellowish crystalline powder. 
 
1H NMR (500.0 MHz, MeOD)  δ: 1.820-1.872(6H,m), 3.661-3.729(4H,m), 3.304(4H,s), 
3.358(4H,d), 1.556(18H,bs) 
13C NMR (125.8 MHz, CDCl3) δ: 170.9, 154.87, 81.02, 51.24, 48.35, 36.51, 28.91(3 C), 27.671 
 
11.10. Second synthesis method of N1,N10-diacetyltriethylenetetramine (DAT) 
 
7. (0.080g, 0.18 mmol) was dissolved in 60% TFA in DCM (3 mL) for the removal of protective 
groups. The reaction mixture was allowed to stir at room temperature for 30 minutes in order to 
ensure thorough mixing. The solvent evaporated and product was dried in vacuo to give N1,N10-
diacetyltriethylenetetramine (DAT) as di trifluoroacetate salt (0.050g, 63%) as off white powder. 
 
1H NMR (500.0 MHz, D2O)  δ: 3.42-3.37(4H, m),3.34 (4H,bs), 3.15-3.11(4H,m), 1.872 (6H,s) 
13C NMR (125.8 MHz, D2O) δ: 175.88, 48.41, 43.58, 36.20, 22.22 
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12. Results and Discussion 
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Synthesis scheme1 The synthesis of DAT  
 
 
In the beginning of research project shown in scheme 1, the starting material N, N´- 
dibenzylethylenediamine was made to react with chloroacetonitrile in the presence of different 
solvents like DMF and ethanol including K2CO3 and KI. The first step of the synthesis in which 
ethanol was used as a solvent produced a mixture of product and by-product ending up having very 
low yield of the original product. When the solvent was changed to DMF a big increase in the 
purity and the yield of the product was observed. This particular route was upgraded to higher 
molar concentrations to get a bigger amount of product 1 for the next step. In second step, the 
reduction of the product 1 obtained from the first step was carried out using LiAlH4 in diethyl ether 
and in THF. The reaction with THF did not proceed well and reaction ended in the partial reduction 
of the product 1. The reaction with diethyl ether produced the product with higher % yield and 
higher purity. Then the molar concentrations of the step with diethyl ether were upgraded to get 
higher amount of the product 2. In third step of the synthesis, the product 2 was acetylated with 
distilled acetic anhydride to get the mono and diacetylated products. Acetic acid and toluene were 
used as solvents during these reaction routes that helped in obtaining the mixture of mono and 
diacetylated products in these reactions. Column chromatography was used in order to get them 
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separated. Only the diacetylated form has been obtained after column chromatography because of 
the presence of very minute quantities of mono acetylated from which were almost impossible to 
separate. After obtaining diacetylated product 3 in the third step, the main aim of the project was to 
remove aromatic protective groups in order to get the desired products. The fourth step of the 
synthesis was catalytic hydrogenation, which was performed at low pressure using (Pd/C) 5% 
catalyst and methanol and toluene as solvents, and also at high pressure using the same catalyst and 
acetic acid along with the methanol to get the DAT as a final product. The deprotection did not take 
place even under high pressure catalytic hydrogenation using acetic acid along with the solvents. 
All these reagents remained unable to cleave the aromatic protective group although they have been 
kept under high pressure catalytic hydrogenation for over night. Hence the deprotection did not 
proceed as planned and has to be optimized. After analysing NMR spectra by both of these 
methods, it is concluded that deprotection or removal of aromatic rings did not work according to 
the synthesis planned. 
 
 
Synthesis scheme2 The synthesis of DAT  
 
In second synthetic route shown in scheme 2, the starting material ethylenediamine was made to 
react with chloroacetonitrile in the presence of dry ACN as a solvent, Cs2CO3 and K2CO3 were also 
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tested as base. The reaction with Cs2CO3 produced lots of impurities and lower yield was obtained 
at the end of the reaction using this base but the reaction route with K2CO3 gave the higher yield of 
product 4 so it was upgraded to get more amount of the product. In the second step, the protection 
of the product 4 was done with the help of Boc protective group. Different solvents were tested in 
this step, like dry triethyleneamine, dry DCM and after words this step was upgraded using the 
same protective group and dry DCM as solvent as they gave the better purity and yield of product 5 
as compared to other solvents used. In the next step, reduction of the product 5 was carried out by 
two parallel reducing agents LiAlH4 and LiAlD4 using diethyl ether as solvent. Both of these 
reduction steps went along quite well in terms of purity of the product 6a and 6b respectively so 
these steps were upgraded using higher molar concentrations of the reagents. In both of these step re 
crystallization of the product was done using ethyl acetate and acetic acid and a better crop of 
crystals is obtained in terms of purity and yield.  The reduction with LiAlD4 is performed in order to 
get deuterated form of the 6a mentioned as 6b in the scheme 2. The next step of acetylation was 
carried out using product 6a as starting material. It was acetylated using dried and distilled acetic 
anhydride and dry ACN as solvent to get mono and diacetylated product in this step. Column 
chromatography was used in order to get them separated and diacetylated product 7 was obtained. 
The deprotection of this product 7 was done using 60% TFA in DCM solution. After analysing the 
NMR spectra of our product 7, we came to know that deprotection went successfully as compared 
to first scheme in order to give us DAT trifuoloroacetate salt as our final product which was one of 
our desired products of the project work. 
 
13. Conclusion 
 
The first synthetic route did not work because of the problems arising from the difficult 
deprotection of the diacetylated product (3). Hence it was concluded that if the problem in 
deprotection can be solved, then this synthesis route can be applied for the synthesis of deuterated 
TETA, MAT and DAT. Anyhow the second synthesis strategy was successfully applied for the 
synthesis of DAT, thus providing the methodology for the synthesis of Deuterated compounds. 
These deuterated polyamines might be used as internal standards in mass spectrometry for their 
quantitative and analytical investigation.  
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